Effect of hydrogen sulfide on myocardial protection in the setting of cardioplegia and cardiopulmonary bypass.
We investigated the impact of hydrogen sulfide (H(2)S) on myocardium in the setting of cold crystalloid cardioplegia and cardiopulmonary bypass (CP/CPB). Eighteen male Yorkshire pigs underwent 1 h CP/CPB followed by 2 h of reperfusion. Pigs received either: placebo (control, n=9), or H(2)S (as NaHS) as a bolus/infusion (bolus/infusion, n=6), or as an infusion (infusion, n=6). The expression pattern of various myocardial effector pathways was investigated. Coronary microvascular relaxation to endothelium-dependent and -independent agonists was assessed. No differences in cardiac function were observed among groups. Endothelium-dependent microvascular relaxation to adenosine diphosphate was improved in the H(2)S bolus/infusion group only (P<0.05). The expression of hemeoxygenase-1, phospho-heat shock proteins27 and phospho-p44/42 MAPK extracellular signal-regulated kinase were higher in H(2)S-treated groups (P<0.05). Phospho-endothelial nitric oxide synthase (P=0.08), phospho-B-cell lymphoma 2 (P=0.09), and phospho-Bad (P=0.06) all displayed a trend to be higher with H(2)S treatment. The expressions of apoptosis inducing factor and Bcl 2/adenovirus E1B 19 kDa-interacting protein were lower in H(2)S treated groups (P<0.05). The microtubule-associated protein 1 light chain 3 ratio was lower in the infusion group vs. control animals (P<0.05). There was a trend for lower phospho-mammalian target of rapamycin expression in the infusion group (P=0.07), whereas phosphorylation of p70S6K1 was higher with H(2)S-treatment (P=0.09). This study demonstrates that H(2)S-treatment may offer biochemical myocardial protection via attenuation of caspase-independent apoptosis and autophagy in the setting of CP/CPB.
Osipov
Robert M
RM
Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, DANA 801, Boston, MA 02215, USA.
Robich
Michael P
MP
Feng
Jun
J
Chan
Vincent
V
Clements
Richard T
RT
Deyo
Ralph J
RJ
Szabo
Csaba
C
Sellke
Frank W
FW
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D001343:Autophagy; D002315:Cardiopulmonary Bypass / Q000009:adverse effects; D002316:Cardiotonic Agents / Q000008:administration & dosage* / Q000097:blood; D002470:Cell Survival; D003326:Coronary Circulation / Q000187:drug effects; D006324:Heart Arrest, Induced / Q000009:adverse effects; D006360:Heat-Shock Proteins / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects; D006862:Hydrogen Sulfide / Q000008:administration & dosage* / Q000097:blood; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D017680:Potassium Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D015427:Reperfusion Injury / Q000209:etiology / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D013552:Swine; D013997:Time Factors; D019210:Troponin I / Q000097:blood; D014664:Vasodilation / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects
D051017:Apoptosis Regulatory Proteins; D002316:Cardiotonic Agents; D006360:Heat-Shock Proteins; D017680:Potassium Compounds; D019210:Troponin I; C018369:potassium cardioplegic solution; D006862:Hydrogen Sulfide